** Shares of U.S. drugmaker Eli Lilly LLY.N fall 1.5% to $856.37 premarket
** Danish rival Novo Nordisk NOVOb.CO reports late-stage data for its experimental next-generation weight-loss drug, CagriSema
** Says CagriSema helped overweight patients with type 2 diabetes (T2D) cut their weight by 15.7% after 68 weeks compared to 3.1% with placebo
** This compares to absolute weight loss of up to ~15.5% shown by LLY's obesity drug Zepbound in T2D patients at week 68 in a late-stage study - Brokerage Leerink Partners
** The CagriSema weight loss data appears a comparable cross-trial to LLY's Zepbound, brokerage says
** Up to last close, LLY stock had risen 11.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。